Beneficial autoimmunity links primary biliary cholangitis to the avoidance of cholangiocarcinoma - Centre de recherche des Cordeliers Accéder directement au contenu
Article Dans Une Revue OncoImmunology Année : 2021

Beneficial autoimmunity links primary biliary cholangitis to the avoidance of cholangiocarcinoma

Résumé

It has been an open conundrum why primary sclerosing cholangitis (PSC) is a major risk factor for developing cholangiocarcinoma (CAA), while primary biliary cholangitis (PBC) is not. In mouse models of PSC and PBC, it turned out that the latter condition, an autoimmune disease affecting the bile ducts, reduces transgene-induced cholangiocarcinogenesis, as well as the progression of subcutaneously implanted CCA. This CCA-delaying effect is lost upon depletion of T lymphocytes and involves tumor infiltration by T cell clonotypes that are also found in PBC lesions. Hence, organ-specific autoimmunity may improve immunosurveillance.
Fichier principal
Vignette du fichier
2162402X.2021.1968595.pdf (1.06 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03350626 , version 1 (21-09-2021)

Identifiants

Citer

Jonathan Pol, Juliette Paillet, Céleste Plantureux, Guido Kroemer. Beneficial autoimmunity links primary biliary cholangitis to the avoidance of cholangiocarcinoma. OncoImmunology, 2021, 10 (1), pp.1968595. ⟨10.1080/2162402x.2021.1968595⟩. ⟨hal-03350626⟩
45 Consultations
29 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More